Bookmark

Add to MyYahoo RSS

Arena Pharmaceuticals News

News on Arena Pharmaceuticals (Ticker: ARNA) continually updated from thousands of sources around the net.

Monday Jul 7 | Seeking Alpha

Arena Prescription Sales OK - CEO Sales Are Not

Sales of Arena Pharmaceuticals prescription anti-obesity drug Belviq are in and are okay this week.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Monday Jul 7 | TheStreet.com

Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Mozilla, TheStreet, Financial Markets

Monday Jul 7 | TheStreet.com

Why Arena Pharmaceuticals (ARNA) Stock Is Dropping Today

TheStreet has in-depth coverage of the sale here . TheStreet Ratings team rates ARENA PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation: "We rate ARENA PHARMACEUTICALS INC a SELL.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets

Monday Jul 7 | Benzinga

Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His Shares

Arena Pharmaceuticals shares plunged Monday on news that its chief executive Jack Lief sold nearly 40 percent of his holdings in the company.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Thu Jul 03, 2014

AmericanBankingNews.com

Arena Pharmaceuticals CEO Unloads $1,307,621 in Stock

Arena Pharmaceuticals CEO Jack Lief sold 223,525 shares of Arena Pharmaceuticals stock in a transaction that occurred on Tuesday, July 1st.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Mon Jun 30, 2014

AmericanBankingNews.com

Insider Selling: Arena Pharmaceuticals Director Sells 2,473 Shares of Stock

Arena Pharmaceuticals Director Donald D. Belcher unloaded 2,473 shares of the company's stock in a transaction dated Friday, June 27th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Fri Jun 27, 2014

AmericanBankingNews.com

Insider Selling: Arena Pharmaceuticals Director Sells 2,473 Shares of Stock

Arena Pharmaceuticals Director Donald D. Belcher sold 2,473 shares of the company's stock in a transaction dated Friday, June 27th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Seeking Alpha

Arena's Belviq Sales Flat Again

Depending on your perspective, Arena Pharmaceuticals is either a company with great long-term potential or a company that is "growing up" from a more speculative play into a play that is based on fundamentals.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals, Marketing

Fri Jun 20, 2014

Seeking Alpha

Belviq Sales Flat - Is Seasonality Coming Into Play?

Sales of the Arena Pharmaceuticals' weight loss drug Belviq were down slightly this week after seeing a nice recovery last week.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Sales

Seeking Alpha

The Anti-Obesity Space Is Not As Simple As Some Think

When we look at the developing anti-obesity space, we often think of Vivus , Arena Pharmaceuticals , and Orexigen .

Comment?

Related Topix: Startups, VIVUS, Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals, Diabetes, Health, Novo Nordisk AS, Erectile Dysfunction

Tue Jun 17, 2014

AmericanBankingNews.com

Arena Pharmaceuticals Short Interest Down 4.6% in May

Arena Pharmaceuticals was the target of a significant drop in short interest in May. As of May 30th, there was short interest totalling 43,940,567 shares, a drop of 4.6% from the May 15th total of 46,073,021 shares, AnalystRatings.NET reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Mon Jun 16, 2014

Seeking Alpha

What Will It Take For Arena Stock To Rise?

It would seem that there are many Arena Pharmaceuticals investors that are frustrated with the action in the stock price and exactly what it will take for the equity to appreciate.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals

Fri Jun 13, 2014

Seeking Alpha

Arena's Belviq Sales Do More Than Recover

It has certainly been an interesting couple of weeks for investors in Arena Pharmaceuticals .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals, Sales

Freshnews

Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference

Arena Pharmaceuticals, Inc. announced today that the company is scheduled to present a corporate overview at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, 2014, at 2:25 p.m. Eastern Time , at the InterContinental Hotel in Boston, Massachusetts.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals, Marketing

Thu Jun 12, 2014

The Motley Fool

Today's Top Biotech Stocks to Watch: Geron Corporation and Arena Pharmaceuticals

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Geron Corporation little reason to make an offer.

Comment?

Related Topix: Startups, Geron, Biotech, Medicine, Healthcare Industry, Arena Pharmaceuticals, Food and Drug Administration

Wed Jun 11, 2014

Customer Interaction Solutions

Orexigen Shares Plummet Following FDA Decision; Glaxo, Theravance...

Below is a look at some of the headlines for companies that made news in the healthcare sector on June 11, 2014.{nfg}Orexigen Therapeutics on announced that the FDA has issued a three-month extension for the review of Orexigen's new weight-loss drug, NB32.The FDA report indicated the reason for the extension was to reach an agreement on the ... (more)

Comment?

Related Topix: Startups, Theravance, Biotech, Orexigen Therapeutics, Marketing, Medicine, Healthcare Industry, Arena Pharmaceuticals

Tue Jun 10, 2014

Seeking Alpha

Orexigen Investors Hope For FDA Approval

Orexigen is just a day away from receiving an FDA decision on its anti-obesity drug, Contrave.

Comment?

Related Topix: Startups, VIVUS, Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••